TICKERNERD
Menu
CAICAIHealthcare · Biotechnology

CAI Stock Forecast: Caris Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$32
+1.96% on the day

The 14 Wall Street analysts covering Caris Life Sciences, Inc. hold a median 12-month price target of $28 — -13.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 23 Sept 2026 — in the lower half.

Market cap
$8.9B
Ticker Nerd rank
37 / 100
Median analyst target
$28
Analysts covering
14
Revenue$263.7M+45.4% y/y
Operating income$26.9M
Net income−$637K
Free cash flow$6.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.4%
1M
+23.5%
YTD
+19.6%
1Y
+6.0%
From 52W high
−2.1%
From 52W low
+121.8%
$15
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Caris Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
75
Value
73
Quality
71
Growth
45
Momentum
38
Accruals
33
Volatility
30
Issuance
19
Size
16

Revisions (75): Analysts have, on balance, been raising their forecasts.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26CAIHigh $36Median $28Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
10 Buy4 Hold0 Sell
Low $22Median $28High $36

The green dot is the last close — the median target sits −13.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
9 Sept 2026UBSInitiatesNeutral$28
6 Aug 2026BTIGMaintainsBuy$32 → $33
6 Aug 2026BTIGMaintainsBuy—
6 Aug 2026Evercore ISI GroupMaintainsOutperform$25 → $26
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$30 → $25
6 July 2026Evercore ISI GroupMaintainsOutperform—
2 July 2026BTIGReiteratesBuy$32
2 July 2026BTIGReiteratesBuy—
2 June 2026Wolfe ResearchAssumesPeer Perform—
8 May 2026BTIGMaintainsBuy—
8 May 2026CitigroupMaintainsBuy—
8 May 2026JP MorganMaintainsOverweight—
13 Apr 2026JefferiesInitiatesBuy—
10 Apr 2026Piper SandlerInitiatesNeutral—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
13 Mar 2026Canaccord GenuityMaintainsHold—
27 Feb 2026BairdMaintainsOutperform—
27 Feb 2026BTIGMaintainsBuy—
27 Feb 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CAI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, Caris Life Sciences, Inc. returned +6.0% against +17.4% for the S&P 500, dividends included.

CAI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26CAIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.3%
Analysts raising
4
Analysts cutting
4
Fundamentals

Caris Life Sciences, Inc. (CAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.2×

Cheaper than 68% of US stocks

Price / sales
9.0×

Cheaper than 16% of US stocks

Price / book
15.0×

Cheaper than 6% of US stocks

EV / EBITDA
49.1×

Cheaper than 5% of US stocks

Growth & margins
Revenue growth (YoY)
45.4%

Higher than 85% of US stocks

Earnings growth (YoY)
45.4%

Higher than 73% of US stocks

Gross margin
68.1%

Higher than 81% of US stocks

Operating margin
10.2%

Higher than 64% of US stocks

Net margin
10.6%

Higher than 71% of US stocks

Returns & dividend
Return on equity
20.1%

Higher than 81% of US stocks

Return on assets
8.8%

Higher than 90% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Caris Life Sciences, Inc. (CAI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Caris Life Sciences, Inc. has a market value of $8.9B and an enterprise value of $8.6B.

  • Revenue in the twelve months to 30 June 2026: $989.6M. The latest quarter grew 45.4% year on year.

  • Net income over the same four quarters: $105.1M, a 10.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.36.

  • Free cash flow in the twelve months to 30 June 2026: $124.0M.

  • Caris Life Sciences, Inc. spent $21.5M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 282.6M.

  • Trailing P/E: 3.2×; forward P/E: 83.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Caris Life Sciences, Inc. employs 1,846 people — $536K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 23 Sept 2026

Data provided by Twelve Data

Peers

CAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CAICaris Life Sciences, Inc.$8.9B
37
TGTXTG Therapeutics, Inc.$8.9B
70
IBRXImmunityBio, Inc.$9.0B
53
PTGXProtagonist Therapeutics, Inc.$8.9B
97
CYTKCytokinetics, Inc.$9.1B
47
CRNXCrinetics Pharmaceuticals, Inc.$8.7B
—
ARWRArrowhead Pharmaceuticals, Inc.$9.4B
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Caris Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CAI news & analysis

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

Market Watch · 23 Sept 2026neutral

FDA advisers are reviewing Grail's Galleri multicancer-detection test, which screens for 50 cancers from a blood draw, though a major study failed to prove it could detect later-stage cancers. Medicare coverage could follow pending the review.

Why it matters — CAI watchers would monitor this since regulatory and Medicare decisions on multicancer-detection tests could shape the competitive landscape for similar diagnostics.

Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look

Investors Business Daily · 22 Sept 2026positive

Investors Business Daily reports that Caris Life Sciences has moved past a buy point, drawing attention to the Texas biotech researcher. Wall Street projects the company turning a net profit of 12 cents a share this year.

Why it matters — The piece highlights Caris Life Sciences crossing a key stock-momentum threshold and analysts' expectation of turning profitable, which a CAI watcher would view as a notable market and financial milestone.

Caris Life Sciences: Diagnostics Growth With Room To Run

Seeking Alpha · 17 Sept 2026positive

Caris Life Sciences is described as having an established profiling business that provides revenue and cash flows to support its expanding diagnostics portfolio. The article notes the company leverages molecular data and clinical relationships to develop new tests and that its Detect offering broadens growth potential, while noting it remains to be seen whether cash-pay adoption and marketing expenses pay off.

Why it matters — This item highlights CAI's existing revenue base and the growth potential of its diagnostics pipeline, which could be relevant to watchers tracking the company's expansion strategy.

Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?

Zacks Investment Research · 16 Sept 2026neutral

Caris Life Sciences, Inc. (CAI) saw a 9.4% gain in its last session on higher-than-average trading volume. However, the latest trend in earnings estimate revisions may not support further upward movement in the near term.

Why it matters — CAI watchers would care because the recent price surge coincided with elevated trading volume, while recent earnings estimate revisions could signal whether the stock's momentum continues or stalls.

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect

PRNewsWire · 8 Sept 2026positive

Caris Life Sciences announced the launch of a new national advertising campaign titled "Math," featuring actor Kevin Costner, to raise awareness of early cancer detection and its multi-cancer early detection blood test, Caris Detect, which is now available nationwide.

Why it matters — A CAI watcher would care because the new national campaign with a prominent celebrity aims to raise public awareness of Caris Detect and expand visibility for the company's early cancer detection offering.

FAQ

Frequently asked questions about CAI stock

What is the CAI stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Caris Life Sciences, Inc. have a median 12-month price target of $28, with estimates ranging from $22 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CAI stock a buy right now?

Of the 14 analysts covering Caris Life Sciences, Inc., 10 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Caris Life Sciences, Inc. 37 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CAI?

As at 23 Sept 2026, Caris Life Sciences, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (75 of 100).

Will CAI stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies -13.2% from the last close, and Ticker Nerd's factor model ranks Caris Life Sciences, Inc. 37 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CAI stock forecast for 2030?

No analyst covering Caris Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $36 over the next 12 months.

How has CAI stock performed over the past year?

Caris Life Sciences, Inc. returned +6.0% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Caris Life Sciences, Inc. do?

Caris Life Sciences, Inc. Common Stock is the equity of Caris Life Sciences, a precision medicine and diagnostics company focused on molecular profiling and anatomic pathology services.

What is the latest news on CAI?

The most recent item we track (Market Watch, 23 Sept 2026): "FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.". FDA advisers are reviewing Grail's Galleri multicancer-detection test, which screens for 50 cancers from a blood draw, though a major study failed to prove it could detect later-stage cancers. Medicare coverage could follow pending the review.

Company

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc. Common Stock is the equity of Caris Life Sciences, a precision medicine and diagnostics company focused on molecular profiling and anatomic pathology services. The company uses advanced molecular information and artificial intelligence to help support cancer detection, disease characterization, treatment selection, and recurrence monitoring. Its current portfolio includes tissue-based and blood-based testing solutions, alongside software-driven tools designed to integrate clinical and molecular data for healthcare providers. Caris Life Sciences serves medical practices, laboratories, researchers, and biopharmaceutical partners across the United States and international markets. Headquartered in Irving, Texas, Caris Life Sciences operates at the intersection of biotechnology, data analytics, and clinical diagnostics, making it an important participant in the healthcare technology market.

CEO Dr. David Dean Halbert M.D. · 1,846 employees · United States · https://www.carislifesciences.com